Moderna Files Lawsuit Against Pfizer and BioNTech Over COVID-19 Vaccines
Angela Weiss/AFP via Getty
Moderna is suing Pfizer and BioNTech over allegations that the biopharmaceutical companies copied their mRNA technology in COVID-19 vaccines without permission.
In a news release Friday, the Cambridge, Massachusetts company stated they plan to file patent infringement lawsuits against Pfizer in the United States District Court of Massachusetts and their German partner BioNTech in the Regional Court of Düsseldorf in Germany.
"We believe that Pfizer and BioNTech unlawfully copied Moderna's inventions, and they have continued to use them without permission," said Moderna Chief Legal Officer Shannon Thyme Klinger.
Klinger continued by saying Moderna expects Pfizer and BioNTech to compensate the company for what he claims are patented technologies. He says a protected patent system "rewards and protects innovation."
Marcos del Mazo/LightRocket via Getty
Never miss a story — sign up for PEOPLE's free weekly newsletter to get the biggest news of the week delivered to your inbox every Friday.
In a statement to PEOPLE, Pfizer said: "Pfizer/BioNTech has not yet fully reviewed the complaint, but we are surprised by the litigation given the Pfizer/BioNTech COVID-19 Vaccine was based on BioNTech's proprietary mRNA technology and developed by both BioNTech and Pfizer."
They added, "We remain confident in our intellectual property supporting the Pfizer/BioNTech vaccine and will vigorously defend against the allegations of the lawsuit."
Moderna said they do not intend on removing the Pfizer vaccine, called Comirnaty, from the market, acknowledging that everyone needs access to these life-saving vaccines, but alleges Pfizer and BioNTech copied two key features of the company's patented technologies to develop their own.
Getty
RELATED: The Women Behind the Vaccine: Meet the Scientists Leading the Fight to End the Pandemic
"We are filing these lawsuits to protect the innovative mRNA technology platform that we pioneers, invested billions of dollars in creating, and patented during the decade preceding the COVID-19 pandemic," said Moderna Chief Executive Officer Stéphane Bancel.